IPO registrations (S-1, F-1) · Registrants
Alaunos Therapeutics, Inc.
- SEC CIK
- 1107421 · filings on EDGAR ↗
- Former names
- ZIOPHARM ONCOLOGY INC (2005–2022); EASYWEB INC (2001–2005)
- Registration
- Form S-1, first filed 2025-10-22; 1 initial registration, 0 amendments
- Outcome
- No final prospectus, effectiveness notice or withdrawal within two years of the registration
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 501 E LAS OLAS BLVD, SUITE 300, Fort Lauderdale, FL 33301
- EIN
- 84-1475642
- Ticker
- TCRT (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Alaunos Therapeutics, Inc. on the corporate pages
On this site
- Business registration: ALAUNOS THERAPEUTICS INC EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: ALAUNOS THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: ALAUNOS THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: ZIOPHARM ONCOLOGY INC EXACT (CIK (EXACT))
- SEC filer: Alaunos Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: George B Abercrombie Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 1
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2025-10-22 | S-1 | S-1 (registration) | Alaunos Therapeutics, Inc. | 0001193125-25-245483 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-22 | S-1 | registration statement | $7.52 | - | - | Nasdaq TRCT | 0 | primary document; price line | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ROSENWALD LINDSAY A MD | TenPercentOwner | 2 | 2006 | ||
| BAGLEY RICHARD E | Director,Officer | President, CCO & Treasurer; President, COO & Treasurer | 14 | 2006–2012 | |
| Fowler Wyche | Director | 21 | 2006–2018 | ||
| FRAGIN GARY S | Director | 9 | 2006–2010 | ||
| GALE ROBERT PETER | Officer | Senior V.P. of Research | 1 | 2006 | |
| LEWIS JONATHAN | Director,Officer | CEO | 24 | 2006–2015 | |
| MCINERNEY TIMOTHY | Director | 24 | 2006–2015 | ||
| WEISER MICHAEL | Director | 23 | 2006–2018 | ||
| CANNON JAMES ANTHONY | Director | 24 | 2006–2019 | ||
| BRENNAN MURRAY | Director | 23 | 2006–2018 | ||
| ESSEX WOODLANDS HEALTH VENTURES FUND VI L P | TenPercentOwner | 2 | 2007–2009 | ||
| SCHWARTZ BRIAN | Officer | V.P. Chief Medical Officer | 1 | 2008 | |
| ABERCROMBIE GEORGE B | Director | 2 | 2010 | person page Fuzzy | |
| INTREXON CORP | TenPercentOwner | 40 | 2011–2018 | ||
| KIRK RANDAL J | Director; Director,TenPercentOwner | 45 | 2011–2018 | ||
| Youssoufian Hagop | Officer | Executive VP, CMO; President of R&D and CMO | 5 | 2011–2013 | |
| BELBEL CAESAR J | Officer | COO, CLO, and Secretary; EVP, Chief Legal Officer & Sec; EVP, CLO, and Secretary | 18 | 2011–2018 | |
| Amello Jason | Officer | Executive Vice President & CFO | 5 | 2012–2013 | |
| Lafond Kevin G | Officer | SVP, Treasurer & CAO; Vice Pres., Treasurer & CAO; Vice Pres., Treasurer, & CAO | 14 | 2013–2021 | |
| LEBEL FRANCOIS | Officer | Executive Vice President R&D | 5 | 2015–2018 | |
| Cooper Laurence James Neil | Director,Officer; Officer | Chief Executive Officer; President and CEO | 14 | 2015–2021 | |
| Tarriff Scott | Director | 7 | 2015–2020 | ||
| MAUNEY DAVID M MD | Officer | EVP and Chief Business Officer; President | 6 | 2017–2020 | |
| Hadfield Robert | Officer | Chief Legal Officer and Sec.; General Counsel and Secretary | 7 | 2018–2021 | |
| Braunstein Scott | Director | 4 | 2018–2020 | ||
| Ezickson Elan | Director | 4 | 2018–2020 | ||
| Pagan Douglas W. | Director | 4 | 2018–2020 | ||
| Hagen Heidi | Director; Director,Officer | Interim CEO | 5 | 2019–2021 | |
| Buck Jill | Officer | EVP, GM Gene Therapy | 5 | 2019–2021 | |
| De Groot Eleanor | Officer | EVP, GM Cell Therapy; EVP, Operations | 7 | 2019–2022 | |
| Shukla Sath | Officer | EVP, Chief Financial Officer | 3 | 2019–2020 | |
| Bowden Christopher | Director | 5 | 2019–2022 | ||
| Huang James | Director | 7 | 2020–2023 | ||
| BUCHI J KEVIN | Director | 3 | 2020–2021 | ||
| Thistle Mary | Director | 5 | 2020–2023 | ||
| Cunningham Timothy M. | Officer | interim CFO | 1 | 2021 | |
| Postma Robert W | Director | 15 | 2021–2026 | ||
| Vieser Jaime | Director | 15 | 2021–2026 | ||
| Weis Holger | Director; Director,Officer; Officer | CEO; Chief Executive Officer | 14 | 2021–2026 | |
| Baffa Raffaele | Officer | Chief Medical Officer | 2 | 2021 | |
| Boyle Kevin S. Sr. | Director,Officer | Chief Executive Officer | 7 | 2021–2023 | |
| Wong Michael | Officer | Vice President, Finance; Vice President of Finance; VP, Finance | 3 | 2021–2023 | |
| Lackey Melinda | Officer | Legal & Administration; See Remarks; Senior Vice President, Legal | 6 | 2021–2025 | |
| Deniger Drew | Officer | See Remarks; VP, Research and Development; VP, Research & Development | 3 | 2022–2023 | |
| Srivastava Abhishek K | Officer | See Remarks | 4 | 2022–2023 | |
| Hofmeister Robert | Director | 4 | 2023–2024 | ||
| Hogue Dale Curtis Jr. | Director; Director,Officer | Interim CEO; See Remarks | 4 | 2024–2025 | |
| Groenewald Ferdinand | Officer | Vice President, Finance; Vice President of Finance; VP, Finance | 4 | 2024–2025 | |
| Jerman Michael Allen | Director | 6 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-09-17 | ZIOPHARM ONCOLOGY INC | Biotechnology | $19,515,153 | $19,515,153 | 1 | 1 |
| 2019-08-09 | ZIOPHARM ONCOLOGY INC | Biotechnology | $105,106,064 | $105,106,064 | 5 | 1 |
| 2018-11-19 | ZIOPHARM ONCOLOGY INC | Biotechnology | $107,007,575 | $50,000,000 | 7 | 1 |
| 2016-07-07 | ZIOPHARM ONCOLOGY INC | Biotechnology | $120,000,000 | $120,000,000 | 1 | 1 |
| 2015-01-28 | ZIOPHARM ONCOLOGY INC | Biotechnology | $57,500,000 | $57,500,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | ALAUNOS THERAPEUTICS, INC. | FL | State business registries | name and state |
| Plan sponsor | ALAUNOS THERAPEUTICS, INC. | TX | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | ZIOPHARM ONCOLOGY INC | MA | Form D private offerings | CIK (EXACT) |
| SEC filer | Alaunos Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | ALAUNOS THERAPEUTICS INC | State business registries | EIN (EXACT, as the state registration reports it) | |
| Form 5500 plan sponsor | ALAUNOS THERAPEUTICS, INC. | EIN (EXACT) | ||
| Person page | George B Abercrombie | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, FL first:
- SANO CORP FL
- CTT PHARMACEUTICAL HOLDINGS, INC. FL
- Inhibitor Therapeutics, Inc. FL
- GENEREX BIOTECHNOLOGY CORP FL
- BIOMOLECULAR LIFE HOLDINGS, INC. FL
- ORAGENICS INC FL
- Polomar Health Services, Inc. FL
- ACCENTIA BIOPHARMACEUTICALS INC FL
- NOMAD POWER SOLUTIONS, INC. FL
- CATALYST PHARMACEUTICALS, INC. FL
In other datasets, the same topic (Health) in FL:
- Nonprofit: 414 WELLWOMEN INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health